Determinants of the bronchodilation response to salbutamol on histamine-induced bronchoconstriction
|
|
- Lily Houston
- 5 years ago
- Views:
Transcription
1 Respiratory Medicine (2006) 100, Determinants of the bronchodilation response to salbutamol on histamine-induced bronchoconstriction Heikki O. Koskela a,, Vesa Kiviniemi b, Minna K. Purokivi a, Antti H. Taivainen a, Hannu O. Tukiainen a a Department of Respiratory Medicine, Kuopio University Hospital, P.O. Box 1777, Kuopio, Finland b IT Centre, Statistical and Mathematical Services, University of Kuopio, P.O. Box 1627, Kuopio, Finland Received 22 November 2005; accepted 1 February 2006 KEYWORDS Bronchial provocation test; Receptor; Adrenergic; Histamine challenge; Salbutamol Summary Assessment of the bronchodilation response to short-acting b 2 -adrenoreceptor agonists on pharmacologically induced bronchoconstriction has often been used to investigate airway smooth muscle b 2 -adrenoreceptor function. However, little is known about factors affecting this response. In the present study, the bronchodilation response to 0.2 mg of salbutamol on histamine-induced bronchoconstriction was assessed in 101 steroid-naïve asthmatic subjects. The associations of the response with a wide range of challenge procedure-related variables, clinical asthma severity indicators, and blood markers of airway inflammation were investigated. The response was re-assessed after 6 and 12 weeks therapy with inhaled budesonide. Baseline FEV 1, final histamine concentration, and the maximal fall in FEV 1 explained 35 59% of the total variation in the response to salbutamol, depending on the index chosen to express the response. Serum concentration of myeloperoxidase, an index of neutrophilic inflammation, was associated with a poor response. The preceding week daily PEF variation, rescue bronchodilator use, severity of asthmatic symptoms, blood eosinophil count, and serum eosinophilic cationic protein and eosinophilic protein X concentrations were not associated with the response. The salbutamol response seemed to diminish during budesonide treatment but when adjusted by the challenge procedure-related variables the treatment effect vanished. In conclusion, the bronchodilation response to salbutamol on histamine-induced bronchoconstriction is largely determined by Corresponding author. Tel.: ; fax: address: heikki.koskela@kuh.fi (H.O. Koskela) /$ - see front matter & 2006 Elsevier Ltd. All rights reserved. doi: /j.rmed
2 Response to salbutamol 1761 challenge procedure-related variables. It seems to be unrelated to the clinical severity of asthma and is not affected by treatment with inhaled corticosteroids. Neutrophilic airway inflammation may be associated with a poor response. & 2006 Elsevier Ltd. All rights reserved. Introduction The bronchodilation response to short-acting b 2 -adrenoreceptor agonists (SABA) can be used to assess airway b 2 -adrenoreceptor function in vivo. It is difficult to assess in stable asthmatic patients in whom there is usually no resting bronchoconstriction. 1,2 Therefore, it has become popular to assess the bronchodilator effect of SABAs on induced bronchoconstriction, especially in studies investigating the development of bronchodilator tolerance to SABAs during regular treatment with b 2 -adrenoreceptor agonists The bronchoconstriction has usually been induced pharmacologically 3 8,11 or, less often, by exercise. 9,10 Given the popularity of the method, surprisingly little is known about the factors associated with the bronchodilation response to SABAs on pharmacologically induced bronchoconstriction. In most of the above-mentioned studies one or all of the following challenge procedure-related factors have usually been considered: baseline lung function (usually expressed as forced expiratory volume in 1 s, FEV 1 ), maximal fall in FEV 1, and the dose/concentration of the stimulus to produce the fall. However, the number of subjects in the treatment arms has usually been small. 3 8 In addition, most of these studies have been cross-over in design and monitoring changes in the bronchodilation response rather than measuring bronchodilation response as an absolute variable. Therefore, variables that are not related to the test have rarely been included in the analysis. Such variables could be the various subject characteristics, severity of the subjects asthmatic symptoms, as well as markers of asthmatic inflammation. Furthermore, knowledge about the effect of inhaled corticosteroids on the bronchodilation response to SABAs on pharmacologically induced bronchoconstriction is limited. This information is relevant as corticosteroids are now a routine part of the asthma management. 12,13 In the present study, the variables associated with the bronchodilation response to salbutamol on histamine-induced bronchoconstriction were determined in a large group of carefully characterised, steroid-naïve asthmatic subjects. In addition, the effect of inhaled budesonide treatment on this response was assessed. The results of the present study may help future investigators who intend to use the bronchodilation response to SABAs on pharmacologically induced bronchoconstriction in order to assess airway b 2 -adrenoreceptor function. Methods Study design The present analysis is based on a patient population which was recruited for a randomised, parallel-group, double-blind study comparing two doses (200 or 800 mg per day) of inhaled budesonide (Pulmicort Turbuhaler s, Astra Draco, Lund, Sweden) during a study period of 12 weeks, with a runin period of 1 week. 14 Detailed information about the methods and subjects is expressed in that publication. The present analysis was divided to two parts. First, the variables associated with the bronchoconstriction were analysed using the baseline data. Second, the effect of budesonide on this response was assessed by comparing the baseline data with the data obtained during the budesonide treatment. Since the two budesonide doses were shown to attenuate the histamine responsiveness similarly, 14 the two treatment arms were analysed together. Measurements Skin prick tests were performed against common aeroallergens and atopy was defined as at least 3 mm wheal reaction to any of the allergens. 15 During the study the patients continuously recorded their peak expiratory flow rates (PEF) before they took their medication in the morning and in the evening (Mini Wright Peak Flow Meter, Clement Clark International, London, UK), their rescue SABA use, as well as adverse reactions. They also recorded their symptoms of asthma separately each day and night as a single score from 0 to 3 (0 ¼ no symptoms, 3 ¼ severe symptoms). Histamine responsiveness was assessed three times, during the run-in phase, and after 6 and 12 weeks treatment. Blood samples were collected four
3 1762 times, during the run-in phase, and after 2, 6 and 12 weeks treatment and the following analyses were performed: The total eosinophil count was calculated by routine differential counting with a Coulter Counter (Coulter STKS, Coulter Electronics Ltd., Luton, UK). The serum eosinophilic cationic protein (ECP), serum eosinophilic protein X (EPX) and serum myeloperoxidase (MPO) were measured with commercially available radioimmunoassay research kits (Pharmacia Diagnostics, Uppsala, Sweden). Subjects One hundred and five adult patients with recently diagnosed asthma were recruited (asthma diagnosed during the last 3 months preceding the study and the symptoms presenting for less than 6 months). One hundred and one patients underwent all the baseline measurements. Ninety-seven patients completed the 12-week treatment period. At baseline, all the patients had to be without regular pharmacological treatment for their asthma and they were allowed only SABAs for rescue treatment. All the patients fulfilled the criteria of asthma by the American Thoracic Society 16 and showed airway hyperresponsiveness (provocative concentration of histamine to induce a 20% fall in FEV 1 (PC 20 ) less or equal to 8 mg/ml). Of the 101 patients at baseline, there were 36 men, 27 current smokers, and 68 atopic subjects. The subjects were mean (SD) 38 (12) years old and their FEV 1 was 87 (10) % of predicted. 17 The daily number of shortacting b 2 -agonist rescue inhalations was 1.4 (1.7) during the run-in phase and only ten subjects (9.9%) used equal or more than four inhalations per day. Signed informed consent was obtained from all subjects and the study was approved by the Ethics Committee of Kuopio University Hospital. Histamine challenge and definitions of the salbutamol response indices The subjects had refrained from taking SABAs for at least 8 h before the challenge. The airway responsiveness to histamine was assessed using a modification of the method by Cockcroft et al., 18 differing from the original in that a dosimetric nebuliser (Spira Elektro 2, Hengityshoitokeskus, Hämeenlinna, Finland) was used. The first nebulised solution was 0.9% saline and the post-saline FEV 1 was taken as the baseline value. After that, histamine was inhaled in doubling concentrations from 0.03 up to 16 mg/ml. The challenge was terminated when a fall X20% in FEV 1 was FEV 1 Maximal fall documented or when the maximal histamine concentration had been administered. The percentage fall in FEV 1 after the final histamine concentration was recorded and defined as the maximal fall. Then the subjects inhaled 0.2 mg of salbutamol from a metered-dose inhaler (Ventoline s, GlaxoWellcome, London, UK). The FEV 1 was measured in duplicate 5 min thereafter, and the better of the two values was used for the analysis. Two indices were used to express the bronchoconstriction (Fig. 1): The bronchodilation was the increase in FEV 1 from the maximal fall value to the post-salbutamol value, expressed as percentage of the baseline value. 5 The residual bronchoconstriction was the percentage change in FEV 1 from the baseline value at 5 min after salbutamol inhalation, 7 with a negative value indicating a smaller FEV 1 value at 5 min post-salbutamol compared with the postsaline value. Statistical analysis Post- After Postsaline final salbutamol histamine concentration H.O. Koskela et al. Residual bronchoconstriction Bronchodilation Figure 1 Indices that were used to express the bronchodilation response to salbutamol on histamine-induced bronchoconstriction. Both the broncho-dilation and the residual bronchoconstriction were expressed as percentage of the post-saline FEV 1. The deviation of the distribution of the salbutamol response indices from a normal distribution was studied by the one-sample Kolmogorov Smirnov test. To define the variables associated with the bronchoconstriction at baseline, an analysis of covariance with backwards directed stepwise procedure was used. The response variables were the bronchodilation and the residual bronchoconstriction. The explanatory variables were the baseline FEV 1 (expressed as % of the predicted 17 ), the final histamine concentration
4 Response to salbutamol 1763 (expressed in doubling concentrations), the histamine-induced maximal fall in FEV 1, sex, age, smoking pack-years, presence of current smoking, presence of atopy, the mean daily number of shortacting b 2 -agonist rescue inhalations during the preceding week, the mean daily symptom score during the preceding week, the mean daily PEF variation during the preceding week, blood eosinophil count, ECP, EPX, and MPO. The first three explanatory variables were defined as test-related variables since they were related to the histamine challenge procedure. To define the variables associated with the serum MPO, a similar analysis of covariance was performed. The adjusted and unadjusted changes over time in salbutamol response were examined applying mixed models. 19 The test-related variables were used as timevarying covariates in the analysis of adjusted change in the bronchodilation and the residual bronchoconstriction. The data were presented as means and 95% confidence intervals. P-values less than 0.05 were considered statistically significant. The statistical analyses were performed using SPSS for Windows Results The factors associated with the bronchodilation response to salbutamol on histamine-induced bronchoconstriction at baseline Both the bronchodilation and the residual bronchoconstriction showed a close-to-normal distribution within the study population. The following variables were statistically significantly associated with bronchodilation (P-value, percentage explained from the total variation in bronchodilation, and the direction of association): baseline FEV 1 (P ¼ 0:018, 2.4%, the larger the baseline FEV 1, the smaller the bronchodilation), final histamine concentration (Po0:001, 20.8%, the larger the histamine concentration, the smaller the bronchodilation), maximal fall (Po0:001, 34.8%, the larger the fall, the larger the bronchodilation), and MPO (P ¼ 0:017, 2.5%, the larger the MPO, the smaller the bronchodilation). The following variables were associated with the residual bronchoconstriction: baseline FEV 1 (P ¼ 0:016, 3.7%, the larger the baseline FEV 1, the larger the residual bronchoconstriction), final histamine concentration (Po0:001, 31.7%, the larger the histamine concentration, the larger the residual bronchoconstriction), and MPO (P ¼ 0:011, 4.2%, the larger the MPO, the larger the residual bronchoconstriction). The preceding week daily PEF variation, rescue SABA use, severity of asthmatic symptoms, blood eosinophil count, and serum ECP and EPX concentrations were not associated with the salbutamol response indices. Since serum level of MPO was the only testunrelated variable that was associated with the salbutamol response indices, its determinants were also defined. The following variables were statistically significantly associated with MPO (P-value, percentage explained from the total variation in MPO, and the direction of association): current smoking (P ¼ 0:005, 3.7%, MPO values were larger in current smokers than in never- or ex-smokers), blood eosinophil count and serum ECP (due to their strong interrelationship they were analysed together; Po0:001, 54.2%, the larger the values, the larger the MPO). The effect of a 12-week treatment with inhaled budesonide on the bronchodilation response to salbutamol on histamineinduced bronchoconstriction When analysing unadjusted data, there were significant changes in both salbutamol response indices. After a 12-week treatment with budesonide the bronchodilation decreased from 24.7 ( )% to 20.9 ( )%, Po0:001, and the residual bronchoconstriction changed from 1.5 ( 2.8 to 0.2)% to 3.8 ( 5.2 to 2.5)%, P ¼ 0:001. However, there were also significant changes in the test-related variables that were shown to be associated with the salbutamol response indices: The baseline FEV 1 (% of predicted) increased 2.1% (P ¼ 0:002), the final histamine concentration increased 1.0 doubling doses (Po0:001), and the maximal fall decreased 1.5% (though not statistically significantly, P ¼ 0:14). The MPO values increased from 463 ( ) mg/l before treatment to 518 ( ) mg/l after treatment (P ¼ 0:02). The treatment-induced change in both salbutamol response indices was statistically significantly associated with the changes in the baseline FEV 1 (P ¼ 0:01), final histamine concentration (Po0:001) and the maximal fall (Po0:001). However, the treatment-induced change in the salbutamol response indices did not associate with the treatment-induced changes in MPO (P ¼ 0:36). When the bronchodilation and the residual bronchoconstriction were adjusted with the
5 1764 Figure 2 Effect of budesonide on bronchodilation (a) and residual bronchoconstriction (b). Closed circles indicate unadjusted values whereas the open circles indicate values that are adjusted with baseline FEV 1, final histamine concentration, and maximal fall in FEV 1. test-related variables, the differences between pre-treatment, 6-week post-treatment and 12- week post-treatment values completely disappeared (P ¼ 0:32 for both salbutamol response indices, Fig. 2). This result indicates that the changes in the bronchodilation and the residual bronchoconstriction were mainly explained by the changes in the test related variables. The results did not change if the two treatment groups were analysed separately and there was no difference between the treatment groups. Discussion H.O. Koskela et al. The present study shows that the bronchodilation response to salbutamol on histamine-induced bronchoconstriction is largely determined by variables that are directly related to the histamine challenge procedure itself, namely the baseline lung function, the final histamine concentration, and the maximal fall in FEV 1. These variables explained 35 59% of the total variation in the salbutamol response, depending on the index chosen. Most variables that were unrelated to the challenge procedure, including various subject characteristics, clinical asthma severity indicators, and eosinophilic inflammation variables were not associated with the response. Indeed, the only challenge-unrelated variable that showed a significant association with the salbutamol response was the serum concentration of MPO, an index of neutrophilic inflammation. 20 The present study also shows that treatment with inhaled budesonide does not affect the salbutamol response when the treatment-induced changes in baseline FEV 1,final histamine concentration, and maximal fall in FEV 1 are taken into account. Studies about the effect of regular treatment with b 2 adrenergic agonists on the bronchodilator effect of SABAs on pharmacologically induced bronchoconstriction 3 8 have often suggested the same test-related variables as the present study. Compared with these studies, the present study includes a considerably larger study group and more detailed information about the various subject characteristics, asthma severity indicators, and markers of asthmatic inflammation. Therefore, the present authors can estimate the relative contribution of the test-related variables and asthma severity-related variables. The results clearly show that the bronchodilation response to salbutamol on histamine-induced bronchoconstriction is mainly determined by directly test-related variables. One may criticise that some of the testrelated variables, like FEV 1 at baseline and the final histamine concentration also measure asthma severity. However, the authors believe that their association with the salbutamol response is technical by nature since the great majority of testunrelated asthma severity indicators showed no association. Thus, the documented association of high FEV 1 before challenge with poor salbutamol response probably does not indicate that mild asthma would be associated with a poor response to b 2 adrenergic agonists but that there is limited room for FEV 1 improvement. Accordingly, the association of high final histamine concentration with poor salbutamol response does not indicate that mild airway hyperresponsiveness would be associated with a poor response to b 2 adrenergic agonists but that the competition between bronchoconstrictor and bronchodilator effects on airway smooth muscle is probably in favour of the former.
6 Response to salbutamol 1765 There was only one completely challenge procedure-unrelated variable that was associated with the salbutamol response: the serum concentration of MPO. Induced sputum neutrophil count correlates well with the sputum MPO level in asthma 21,22 and MPO is widely used as an index of neutrophilic inflammation. 20 In the present study, MPO was measured from serum and it is difficult to estimate how well it reflects the neutrophilic inflammation within the airways. In previous studies those asthmatic subjects with a predominantly neutrophilic airway inflammation have shown a poor increase in FEV 1 after a course with either inhaled 22,23 or oral 22 corticosteroids suggesting that neutrophilic inflammation may be involved in the pathophysiology of irreversible airflow obstruction in asthma. Assuming that serum MPO does reflect the neutrophilic inflammation within the airways, the present study is the first to suggest that neutrophil-dominated airway inflammation may also be associated with a poor bronchodilation response to salbutamol on induced bronchoconstriction. In the present population, serum MPO level correlated closely with the indices of eosinophilic inflammation and, much less clearly, with current smoking. It has been shown previously that in severe asthma, eosinophils and neutrophils are usually found together in the airways 24 and that smoking induces neutrophilic airway inflammation in mild asthma. 25 Taken together, these findings suggest that neutrophilic airway inflammation is typical for an asthmatic patient with severe eosinophilic airway inflammation, and may be enhanced by smoking. Interestingly, neither indices of eosinophilic inflammation nor smoking habits were independent determinants of the salbutamol response, highlighting the role of neutrophilic inflammation in this respect. Treatment with budesonide did not affect the bronchoconstriction though it had clear effects on the patient s asthmatic symptoms, lung function, histamine responsiveness, and indices of eosinophilic inflammation (as previously reported by Tukiainen et al. 14 ). This fits to the above-mentioned concept that this response to salbutamol has little to do with the clinical severity of patient s asthma. The lack of effect by budesonide on the salbutamol response may also be explained by the fact that inhaled corticosteroids do not suppress the airway neutrophilic inflammation whereas their effect on eosinophilic inflammation is clear. 26,27 In fact, the serum MPO levels actually increased during the budesonide treatment in the present study. This could be explained by the fact that corticosteroids can inhibit neutrophil apoptosis and phagocytic removal and yet induce the same process in eosinophils. 28,29 Limitations of the study One may criticise that the observation time after the salbutamol dose (5 min) was too short to fully reveal the salbutamol response. However, the baseline histamine challenge showed that the FEV 1 was just 1.5% lower at 5 min post-salbutamol compared with the post-saline FEV 1 (the residual bronchoconstriction ). The authors therefore believe that a longer observation time would not have changed the results significantly. In fact, the rather short observation time after salbutamol ensured that the spontaneous recovery after histamine challenge (30 60 min in adults 30 ) did not interfere with the salbutamol response. The authors way to measure inflammatory indices from blood samples instead of sputum samples may also be considered as a weakness. However, by this way the authors could measure these indices in all subjects whereas as many as a quarter of subjects may produce inadequate samples in response to sputum induction, 31 which can be a cause of a selection bias. Finally, as the present study was not placebocontrolled, the authors cannot define whether the documented increase in MPO during budesonide treatment was a true treatment effect. Conclusion In conclusion, the bronchodilation response to salbutamol on histamine-induced bronchoconstriction seems to be mainly determined by test-related technical variables. This response is unrelated to the clinical severity of asthma and is not affected by treatment with inhaled budesonide. Neutrophilic airway inflammation may be associated with a poor response. Acknowledgements The budesonide preparations were provided by Astra Finland Oy, Masala, Finland. References 1. Grove A, Lipworth BJ. Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol. Thorax 1996;51:585 9.
7 1766 H.O. Koskela et al. 2. Langley SJ, Masterson CM, Batty EP, Woodcock A. Bronchodilator response to salbutamol after chronic dosing with salmeterol or placebo. Eur Respir J 1998;11: Hancox RJ, Aldridge RE, Cowan JO, et al. Tolerance to betaagonists during acute bronchoconstriction. Eur Respir J 1999;14: Jones SL, Cowan JO, Flannery EM, Hancox RJ, Herbison GP, Taylor DR. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. Eur Respir J 2001;17: van der Woude HJ, Winter TH, Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists. Thorax 2001;56: Wraight JM, Hancox RJ, Herbison GP, Cowan JO, Flannery EM, Taylor DR. Bronchodilator tolerance: the impact of increasing bronchoconstriction. Eur Respir J 2003;21: Lee DK, Jackson CM, Bates CE, Lipworth BJ. Cross tolerance to salbutamol occurs independently of beta2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol. Thorax 2004;59: Haney S, Hancox RJ. Rapid onset of tolerance to betaagonist bronchodilation. Respir Med 2005;99: Hancox RJ, Subbarao P, Kamada D, Watson RM, Hargreave FE, Inman MD. Beta2-agonist tolerance and exercise-induced bronchospasm. Am J Respir Crit Care Med 2002;165: Storms W, Chervinsky P, Ghannam AF, Bird S, Hustad CM, Edelman JM. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir Med 2004;98: Cho SH, Oh SY, Bahn JW, et al. Association between bronchodilating response to short-acting beta-agonist and non-synonymous single-nucleotide polymorphisms of betaadrenoceptor gene. Clin Exp Allergy 2005;35: National Heart Lung and Blood Institute. Global initiative for asthma. Global strategy for asthma management and prevention. NHLBI/WHO workshop report. National Heart Lung and Blood Institute publication number , British guideline on the management of asthma. Thorax 2003;58(Suppl. 1):i1 i Tukiainen H, Taivainen A, Majander R, et al. Comparison of high and low dose of the inhaled steroid, budesonide, as an initial treatment in newly detected asthma. Respir Med 2000;94: The European Academy of Allergology and Clinical Immunology. Position paper: allergen standardization and skin tests. Allergy 1993;48: American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive lung disease (COPD) and asthma. Am Rev Respir Dis 1987;136: Viljanen AA, Halttunen PK, Kreus K-E, Viljanen BC. Spirometric studies in non-smoking, healthy adults. Scand J Clin Lab Invest 1982;42: Cockcroft DW, Killian DN, Mellon JJ, Hargreave FE. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 1977;7: Brown H, Prescott R. Applied mixed models in medicine. Chichester: Wiley; Klebanoff SJ. Myeloperoxidase. Proc Assoc Am Physicians 1999;111: Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999;160: Little SA, MacLeod KJ, Chalmers GW, Love JG, McSharry C, Thomson NC. Association of forced expiratory volume with disease duration and sputum neutrophils in chronic asthma. Am J Med 2002;112: Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57: Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160: Chalmers GW, MacLeod KJ, Thomson L, Little SA, McSharry C, Thomson NC. Smoking and airway inflammation in patients with mild asthma. Chest 2001;120: Hoshino M, Nakamura Y. Anti-inflammatory effects of inhaled beclomethasone dipropionate in nonatopic asthmatics. Eur Respir J 1996;9: Nguyen LT, Lim S, Oates T, Chung KF. Increase in airway neutrophils after oral but not inhaled corticosteroid therapy in mild asthma. Respir Med 2005;99: Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol 1995;154: Liu Y, Cousin JM, Hughes J, et al. Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes. J Immunol 1999;162: Polosa R, Prosperini G, Magri S, et al. Bronchodilator response to salbutamol after spontaneous recovery from nonspecific bronchial provocation tests in asthma. Eur Respir J 1998;11: Pin I, Gibson PG, Kolendowicz R, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992;47:25 9.
THE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Vol 120 No 1267 ISSN 1175 8716 Is Salamol less effective than Ventolin? A randomised, blinded, crossover study in New Zealand Catherina L Chang, Manisha Cooray, Graham Mills,
More informationEvidence-based recommendations or Show me the patients selected and I will tell you the results
Respiratory Medicine (2006) 100, S17 S21 Evidence-based recommendations or Show me the patients selected and I will tell you the results Leif Bjermer Department of Respiratory Medicine & Allergology, 221
More informationTolerance to beta-agonists during acute bronchoconstriction
Eur Respir J 1999; 14: 283±287 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 0903-1936 Tolerance to beta-agonists during acute bronchoconstriction
More informationC linicians have long regarded asthma as a heterogeneous
875 ORIGINAL ARTICLE Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids R H Green, C E Brightling,
More informationBUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationTolerance to bronchodilating effects of salmeterol in COPD
Respiratory Medicine (2003) 97, 1014 1020 Tolerance to bronchodilating effects of salmeterol in COPD J.F. Donohue a, *, S. Menjoge b, S. Kesten b a University of North Carolina School of Medicine, 130
More informationInhaled corticosteroid effects both eosinophilic and non-eosinophilic inflammation in asthmatic patients
Research Communication Mediators of Inflammation, 13(4), 285/291 (August 2004) AIM: To determine induced sputum cell counts and interleukin-8 (IL-8), tumor necrosis factor alpha (TNF-a) and leukotriene
More informationBronchial asthma. MUDr. Mojmír Račanský Odd. Alergologie a klinické imunologie FNOL Ústav Imunologie LF UPOL
Bronchial asthma MUDr. Mojmír Račanský Odd. Alergologie a klinické imunologie FNOL Ústav Imunologie LF UPOL DEFINITION ASTHMA BRONCHIALE = Asthma is a chronic inflammatory disorder of the airways in which
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationReversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol
Eur Respir J 2001; 17: 368 373 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 Reversing acute bronchoconstriction in asthma: the effect of
More informationSalmeterol, a new long acting inhaled,f2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients
Thorax 1988;43:674-678 Salmeterol, a new long acting inhaled,f2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients ANDERS ULLMAN, NILS SVEDMYR From the Department of Clinical
More informationClinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving
More informationAdenosine 5 0 -monophosphate increases levels of leukotrienes in breath condensate in asthma
Respiratory Medicine (2004) 98, 651 655 Adenosine 5 0 -monophosphate increases levels of leukotrienes in breath condensate in asthma E. Bucchioni, Z. Csoma, L. Allegra, K.F. Chung, P.J. Barnes, S.A. Kharitonov*
More informationAirway inflammation in patients with symptoms suggesting asthma but with normal lung function
Eur Respir J 2; 16: 824±83 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 2 European Respiratory Journal ISSN 93-1936 Airway inflammation in patients with symptoms suggesting asthma but
More informationMechanisms of action of bronchial provocation testing
Mechanisms of action of bronchial provocation testing TSANZ / ANZSRS Masterclass: April 3rd, 2016 13:00 13:30 John D. Brannan PhD Scientific Director - Dept. Respiratory & Sleep Medicine John Hunter Hospital,
More informationHCT Medical Policy. Bronchial Thermoplasty. Policy # HCT113 Current Effective Date: 05/24/2016. Policy Statement. Overview
HCT Medical Policy Bronchial Thermoplasty Policy # HCT113 Current Effective Date: 05/24/2016 Medical Policies are developed by HealthyCT to assist in administering plan benefits and constitute neither
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationComparison of the Effect of Short Course of Oral Prednisone in Patients with Acute Asthma
ISPUB.COM The Internet Journal of Pulmonary Medicine Volume 7 Number 1 Comparison of the Effect of Short Course of Oral Prednisone in Patients with Acute Asthma E Razi, G Moosavi Citation E Razi, G Moosavi.
More informationT he development of tolerance following the use of long
662 ASTHMA Cross tolerance to salbutamol occurs independently of b 2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol D K C Lee, C M Jackson, C E Bates, B J Lipworth...
More informationDo current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma?
Respiratory Medicine (2006) 100, 458 462 Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma? Haim S. Bibi a,, David Feigenbaum a, Mariana Hessen
More informationAbstract Background Theophylline is widely used in the treatment of asthma, and there is evidence that theophylline has antiinflammatory
Thorax 2000;55:837 841 837 National Heart and Lung Institute, Imperial College School of Medicine and Royal Brompton Hospital, London SW3 6LY, UK S Lim A Jatakanon K F Chung P J Barnes Napp Laboratories
More informationAn inhaled steroid improves markers of airway inflammation in patients with mild asthma
Eur Respir J 998; : 8 88 DOI:.8/996.98.8 Printed in UK - all rights reserved Copyright ERS Journals Ltd 998 European Respiratory Journal ISSN 9-96 An inhaled steroid improves markers of airway inflammation
More informationNON-SPECIFIC BRONCHIAL HYPERESPONSIVENESS. J. Sastre. Allergy Service
NON-SPECIFIC BRONCHIAL HYPERESPONSIVENESS J. Sastre. Allergy Service Asthma: definition Asthma is a syndrome defined on basis of three main aspects: 1- Symptoms due to variable and reversible airway obstruction
More informationEffect of 1 year daily treatment with 400 µg budesonide (Pulmicort Turbuhaler ) in newly diagnosed asthmatics
Eur Respir J 1997; 10: 2210 2215 DOI: 10.1183/09031936.97.10102210 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 0903-1936 Effect of 1 year daily
More informationComparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma
Eur Respir J 2002; 20: 66 72 DOI:.83/0903936.02.00094202 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-936 Comparison of anti-inflammatory and
More informationStrategy Aimed at Reduction of Sputum Eosinophils Decreases Exacerbation Rate in Patients with Asthma
The Journal of International Medical Research 2006; 34: 129 139 Strategy Aimed at Reduction of Sputum Eosinophils Decreases Exacerbation Rate in Patients with Asthma J CHLUMSKÝ 1, I STRIZ 2, M TERL 3 AND
More informationA comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge
Respiratory Medicine (2004) 98, 1051 1062 A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge William Storms a, Paul Chervinsky
More informationThe Use of Exhaled Nitric Oxide to Guide Asthma Management: A Randomised Controlled Trial
The Use of Exhaled Nitric Oxide to Guide Asthma Management: A Randomised Controlled Trial DE Shaw, MA Berry, M Thomas, RH Green, CE Brightling, AJ Wardlaw and ID Pavord. Institute for Lung Health, Department
More informationEffect of inhaled budesonide therapy on lung function in schoolchildren born preterm
RESPIRATORY MEDICINE (2001) 95, 565 570 doi:10.1053/rmed.2001.1104, available online at http://www.idealibrary.com on Effect of inhaled budesonide therapy on lung function in schoolchildren born preterm
More informationPeak Expiratory Flow Variability Adjusted by Forced Expiratory Volume in One Second is a Good Index for Airway Responsiveness in Asthmatics
ORIGINAL ARTICLE Peak Expiratory Flow Variability Adjusted by Forced Expiratory Volume in One Second is a Good Index for Airway Responsiveness in Asthmatics Kazuto Matsunaga, Masae Kanda, Atsushi Hayata,
More informationAsthma Pathophysiology and Treatment. John R. Holcomb, M.D.
Asthma Pathophysiology and Treatment John R. Holcomb, M.D. Objectives Definition of Asthma Epidemiology and risk factors of Asthma Pathophysiology of Asthma Diagnostics test of Asthma Management of Asthma
More informationChronic Cough Due to Nonasthmatic Eosinophilic Bronchitis. ACCP Evidence-Based Clinical Practice Guidelines
Chronic Cough Due to Nonasthmatic Eosinophilic Bronchitis ACCP Evidence-Based Clinical Practice Guidelines Christopher E. Brightling, MBBS, PhD, FCCP Objectives: Nonasthmatic eosinophilic bronchitis is
More informationCurrent Asthma Management: Opportunities for a Nutrition-Based Intervention
Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent
More informationBudesonide treatment of moderate and severe asthma in children: A doseresponse
Budesonide treatment of moderate and severe asthma in children: A doseresponse study Soren Pedersen, MD, PhD, and Ove Ramsgaard Hansen, MD Kolding, Denmark Objective: The purpose of the study was to evaluate
More informationInflammation in chronic obstructive pulmonary disease : its assessment and the effects of corticosteroids Boorsma, M.
UvA-DARE (Digital Academic Repository) Inflammation in chronic obstructive pulmonary disease : its assessment and the effects of corticosteroids Boorsma, M. Link to publication Citation for published version
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationInhaled fluticasone decreases bronchial but not alveolar nitric oxide output in asthma
Eur Respir J 21; 18: 635 639 Printed in UK all rights reserved Copyright #ERS Journals Ltd 21 European Respiratory Journal ISSN 93-1936 Inhaled fluticasone decreases bronchial but not alveolar nitric oxide
More informationAirway calibre as a confounder in interpreting
702 Medical Department TTA 7511, State University Hospital, Copenhagen, Denmark A Dirksen F Madsen T Engel L Frolund J H Heing H Mosbech Reprint requests to: Dr A Dirksen, Department of Pulmonary Medicine
More informationDifferential Effect of Formoterol on Adenosine Monophosphate and Histamine Reactivity in Asthma
Differential Effect of Formoterol on Adenosine Monophosphate and Histamine Reactivity in Asthma JULIA A. NIGHTINGALE, DUNCAN F. ROGERS, and PETER J. BARNES Thoracic Medicine, National Heart and Lung Institute,
More informationInduced sputum to assess airway inflammation: a study of reproducibility
Clinical and Experimental Allergy. 1997. Volume 27. pages 1138-1144 Induced sputum to assess airway inflammation: a study of reproducibility A. SPANEVELLO, G. B. MIGLIORI. A. SHARARA*, L. BALLARDlNIt,
More informationCOPD and Asthma: Similarities and differences Prof. Peter Barnes
and Asthma: Similarities and Differences and Asthma: 1 Imperial College Peter Barnes FRS, FMedSci, National Heart & Lung Institute Imperial College, London, UK p.j.barnes@imperial.ac.uk Royal Brompton
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationEffect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma
Eur Respir J 2001; 17: 374 379 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 Effect of oral prednisolone on the bronchoprotective effect
More informationBronchial hyperresponsiveness in asthmatic adults A long-term correlation study
European Review for Medical and Pharmacological Sciences 2005; 9: 125-131 Bronchial hyperresponsiveness in asthmatic adults A long-term correlation study R. CARBONE, F. LUPPI *, A. MONSELISE **, G. BOTTINO
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationOccupational asthma is a disease characterised. Workplace-specific challenges as a contribution to the diagnosis of occupational asthma
Eur Respir J 2008; 32: 997 1003 DOI: 10.1183/09031936.00100207 CopyrightßERS Journals Ltd 2008 Workplace-specific challenges as a contribution to the diagnosis of occupational asthma J-P. Rioux, J-L. Malo,
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationStep-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.
Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide. By: DR MOHD SHAMSUL AMRI Supervisor: Associate Professor Dr
More informationLow- and high-dose fluticasone propionate in asthma; effects during and after treatment
Eur Respir J 2000; 15: 11±18 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 2000 European Respiratory Journal ISSN 0903-1936 Low- and high-dose fluticasone propionate in asthma; effects
More informationInfluence of Beclomethasone and Salmeterol on the Perception of Methacholine-Induced Bronchoconstriction*
Influence of Beclomethasone and Salmeterol on the Perception of Methacholine-Induced Bronchoconstriction* Louis-Philippe Boulet, MD, FCCP; Helene Turcotte, MS; Andre Cartier, MD; Joanne Milot, BS; Johanne
More informationAllergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al.
Allergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al. Chapter 75: Approach to Infants and Children with Asthma
More informationMario Cazzola, MD, FCCP; Gabriele Di Lorenzo, MD; Felice Di Perna, MD; Francesco Calderaro, MD; Renato Testi, MD; and Stefano Centanni, MD
Additive Effects of Salmeterol and Fluticasone or Theophylline in COPD* Mario Cazzola, MD, FCCP; Gabriele Di Lorenzo, MD; Felice Di Perna, MD; Francesco Calderaro, MD; Renato Testi, MD; and Stefano Centanni,
More informationEffects of Terbutaline and Budesonide on Sputum Cells and Bronchial Hyperresponsiveness In Asthma
Effects of Terbutaline and Budesonide on Sputum Cells and Bronchial Hyperresponsiveness In Asthma RUTH E. ALDRIDGE, ROBERT J. HANCOX, D. ROBIN TAYLOR, JAN O. COWAN, MARTI C. WINN, CHRIS M. FRAMPTON, and
More informationDiagnosis, Treatment and Management of Asthma
Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.
More informationG. Boyd on behalf of a UK Study group
Eur Respir J, 1995, 8, 1494 1498 DOI: 10.1183/09031936.95.08091494 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Salmeterol xinafoate in
More informationT he use of inhaled corticosteroids in stable chronic
193 CHRONIC OBSTRUCTIVE PULMONARY DISEASE Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease C E Brightling, S McKenna, B Hargadon, S Birring,
More informationBronchodilator Response in Patients with Persistent Allergic Asthma Could Not Predict Airway Hyperresponsiveness
ORIGINAL ARTICLE Bronchodilator Response in Patients with Persistent Allergic Asthma Could Not Predict Airway Hyperresponsiveness Bojana B. Petanjek, MD, Sanja P. Grle, MD, Dubravka Pelicarić, MD, and
More informationAsthma exacerbations and sputum eosinophil counts: a randomised controlled trial
Articles Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial Ruth H Green, Christopher E Brightling, Susan McKenna, Beverley Hargadon, Debbie Parker, Peter Bradding, Andrew
More informationMild Exacerbations and Eosinophilic Inflammation in Patients With Stable, Well-Controlled Asthma After 1 Year of Follow-up*
Mild Exacerbations and Eosinophilic Inflammation in Patients With Stable, Well-Controlled Asthma After 1 Year of Follow-up* Jose Belda, MD, PhD; Jordi Giner, RN; Pere Casan, MD, PhD; and Joaquin Sanchis,
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationAirways hyperresponsiveness to different inhaled combination therapies in adolescent asthmatics
Airways hyperresponsiveness to different inhaled combination therapies in adolescent asthmatics Daniel Machado 1, MD Celso Pereira 1,2, MD, PhD Beatriz Tavares 1, MD Graça Loureiro 1, MD António Segorbe-Luís
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationClinical Study Principal Components Analysis of Atopy-Related Traits in a Random Sample of Children
International Scholarly Research Network ISRN Allergy Volume 2011, Article ID 170989, 4 pages doi:10.5402/2011/170989 Clinical Study Principal Components Analysis of Atopy-Related Traits in a Random Sample
More informationRespiratory Pharmacology
Allergy Targets of allergies Type I Histamine Leukotrienes Prostaglandins Bradykinin Hypersensitivity reactions Asthma Characterised by Triggered by Intrinsic Extrinsic (allergic) Mediators Result Early
More informationStudy designs and PD/Clinical endpoints to demonstrate therapeutic equivalence: European Views
IPAC-RS/University of Florida Study designs and PD/Clinical endpoints to demonstrate therapeutic equivalence: European Views 20 th March 2014 Dr. Alfredo García - Arieta Head of the Service of Generic
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationPotency ratio fluticasone propionate (Flixotide Diskus)/budesonide (Pulmicort Turbuhaler)
Respiratory Medicine (2007) 101, 610 615 Potency ratio fluticasone propionate (Flixotide Diskus)/budesonide (Pulmicort Turbuhaler) Björn Ställberg a, Eva Pilman b, Bengt-Eric Skoogh c,, Bengt Arne Hermansson
More informationAssociation between asthma control and bronchial hyperresponsiveness and airways inflammation: a cross-sectional study in daily practice
Association between asthma control and bronchial hyperresponsiveness and airways inflammation: a cross-sectional study in daily practice V. Quaedvlieg, J. Sele, M. Henket and R. Louis Department of Respiratory
More informationEffect of disease duration on dose response of inhaled budesonide in asthma
Respiratory Medicine (2008) 102, 1065 1072 Effect of disease duration on dose response of inhaled budesonide in asthma Olof Selroos a,b, a Mjölbolsta Hospital, Karis, Finland b SEMECO AB, Skogsvägen 5,
More informationBronchial Thermoplasty
Bronchial Thermoplasty Policy Number: 7.01.127 Last Review: 9/2014 Origination: 11/2010 Next Review: 3/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage for bronchial
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationLeukotriene C 4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma
Blackwell Science, LtdOxford, UKBCPBritish Journal of Clinical Pharmacology0306-5251Blackwell Publishing 2003? 2003564422426Original ArticleLeukotriene C4 synthasej. J. Lima et al. Leukotriene C 4 synthase
More informationCoughing During Mannitol Challenge Is Associated With Asthma*
clinical investigations Coughing During Mannitol Challenge Is Associated With Asthma* Heikki O. Koskela, MD; Liisa Hyvärinen, MD; John D. Brannan, PhD; Hak-Kim Chan, PhD; and Sandra D. Anderson, PhD, DSc
More informationThe New England Journal of Medicine
A COMPARISON OF LOW-DOSE INHALED BUDESONIDE PLUS THEOPHYLLINE AND HIGH-DOSE INHALED BUDESONIDE FOR MODERATE ASTHMA DAVID J. EVANS, M.B., DAVID A. TAYLOR, M.B., OLLE ZETTERSTROM, M.D., K. FAN CHUNG, M.D.,
More information), the dose of histamine required to provoke a fall in FEV 1. of more than 20% (PD 20
Thorax 1999;54:103 107 103 Pulmonology, Isala Clinics/Weezenlanden Hospital, 00 GM Zwolle, The P L P Brand Pulmonology, Juliana The Hague, The E J Duiverman Pulmonology, Beatrix Groningen, The H J Waalkens
More informationSupplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus
Supplementary Medications during asthma attack Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Conflicts of Interest None Definition of Asthma Airway narrowing that is
More informationDiagnosing Asthma Comparisons between Exhaled Nitric Oxide Measurements and Conventional Tests
Diagnosing Asthma Comparisons between Exhaled Nitric Oxide Measurements and Conventional Tests Andrew D. Smith, Jan O. Cowan, Sue Filsell, Chris McLachlan, Gabrielle Monti-Sheehan, Pamela Jackson, and
More informationC ough variant asthma, gastro-oesophageal reflux associated
14 ASTHMA Comparison of atopic cough with cough variant asthma: is atopic cough a precursor of asthma? M Fujimura, H Ogawa, Y Nishizawa, K Nishi... See end of article for authors affiliations... Correspondence
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/21235
More informationBeta 2 adrenoceptor agonists and the Olympic Games in Athens
Beta 2 adrenoceptor agonists and the Olympic Games in Athens 1 Appendix A of the Olympic Movement Anti-Doping Code, the List of Prohibited Substances and Prohibited Methods dated 1 st January 2003 states
More information#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationComparison of exhaled nitric oxide measurements between NIOX MINO â electrochemical and Ecomedics chemiluminescence analyzer
Respiratory Medicine (2008) 102, 1667e1671 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed SHORT COMMUNICATION Comparison of exhaled nitric oxide measurements between
More informationExhaled nitric oxide and sputum eosinophil markers of inflammation in asthmatic children
Eur Respir J 1999; 13: 1386±1390 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 0903-1936 Exhaled nitric oxide and sputum eosinophil markers of inflammation
More informationThirteen-year follow-up of early intervention with an inhaled corticosteroid in patients with asthma
Asthma and lower airway disease Thirteen-year follow-up of early intervention with an inhaled corticosteroid in patients with asthma Tari Haahtela, MD, PhD, a Klaus Tamminen, MD, a Tuomo Kava, MD, PhD,
More informationScottish Medicines Consortium
Scottish Medicines Consortium budesonide/formoterol 100/6, 200/6 turbohaler (Symbicort SMART ) No. (362/07) Astra Zeneca UK Limited 9 March 2007 (Issued May 2007) The Scottish Medicines Consortium (SMC)
More informationProf Neil Barnes. Respiratory and General Medicine London Chest Hospital and The Royal London Hospital
Prof Neil Barnes Respiratory and General Medicine London Chest Hospital and The Royal London Hospital ASTHMA: WHEN EVERYTHING FAILS WHAT DO YOU DO? South GP CME 2013, Dunedin Saturday 17 th August 2013
More informationW e have shown in a previous meta-analysis of placebo
16 ASTHMA Clinical dose-response relationship of fluticasone propionate in adults with asthma M Masoli, M Weatherall, S Holt, R Beasley... See end of article for authors affiliations... Correspondence
More informationResearch Article Exercise-Induced Asthma Symptoms and Nighttime Asthma: Are They Similar to AHR?
Allergy Volume 2009, Article ID 378245, 6 pages doi:10.1155/2009/378245 Research Article Exercise-Induced Asthma Symptoms and Nighttime Asthma: Are They Similar to AHR? V. Backer and L. M. Rasmussen Department
More informationSubclinical phenotypes of asthma
1 Subclinical phenotypes of asthma P Bradding DM FRCP*, RH Green MD FRCP* * Institute for Lung Health and Department of Respiratory Medicine, Glenfield Hospital, Leicester, UK Department of Infection,
More informationAir Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation.
Asthma Air Flow Limitation In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation. True whether reversible, asthma and exercise-induced bronchospasm,
More informationComparison of Peak Expiratory Flow Variability Between Workers With Work- Exacerbated Asthma and Occupational Asthma*
CHEST Comparison of Peak Expiratory Flow Variability Between Workers With Work- Exacerbated Asthma and Occupational Asthma* Samah Chiry, MD; André Cartier, MD; Jean-Luc Malo, MD; Susan M. Tarlo, MD, FCCP;
More informationmeasured Improvement in am PEFR FP vs BUD gave +11l/min FP vs BDP gave nonsignificant improvement in PEFR +3l/min FP: BUD ratio 1.
1 of 8 09/05/2018, 11:29 Guideline topic: Pharmacological management of asthma Evidence table 4.25: Budesonide vs Beclomethasone Different inhaled corticosteroids (ICS) flixotide propionate (FP) vs budesonide
More informationInternational Journal of Medical Science and Education pissn eissn
COMPARISON OF MONTELUKAST AND KETOTIFEN AS ADD ON THERAPY IN MODERATE AND SEVERE PERSISTENT BRONCHIAL ASTHMA Dr. Gaurav Chhabra 1, Dr. Shubhakaran Sharma 2* Original research article 1,2 Associate professor,
More informationAsthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
More informationAsthma - Chronic. Presentations of asthma Cough Wheeze Breathlessness Chest tightness
Asthma - Chronic Definition of asthma Chronic inflammatory disease of the airways 3 components: o Reversible and variable airflow obstruction o Airway hyper-responsiveness to stimuli o Inflammation of
More informationCOPD or not COPD, that is the question.
COPD or not COPD, that is the question. Asthma-COPD Overlap Syndrome: ACOS Do we really need this? Michelle Harkins Disclosure Slide Slide help - William Busse, MD Organizational Interests ATS, ACCP, ACP
More informationProperty of Presenter
Have We Missed A Role For Neutrophils In Asthma? In Steroid-Refractory Asthma? Erwin W. Gelfand, MD Chairman, Department of Pediatrics National Jewish Health Professor of Pediatrics and Immunology University
More information